Patents by Inventor Fernando José Corrales Izquierdo

Fernando José Corrales Izquierdo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSTIONS DESIGNED FOR THE INHIBITION AND/OR BLOCKING OF THE EPITHELIAL/MESENCHYMAL TRANSITION
    Publication number: 20120220546
    Abstract: 5?-methylthioadenosine (MTA) is described as a compound that is susceptible to inhibiting and/or blocking the epithelial-mesenchymal transition (EMT), a process whereby epithelial cells become mesenchymal cells. The periodical intake of MTA [every 24 h for 21 days] significantly improves fibrosis and the markers for hepatic cellular damage in KO-Mdr2 mice with MTA (28 mg/kg). Following the daily oral administration of MTA, both the expression of EMT markers in the total liver and appreciable signs of fibrosis are significantly reduced, indicating the beneficial effect of MTA on the liver affected by the lack of Mdr2. MTA is proposed to be a safe drug, suitable for oral formulation and without secondary effects, to be used in the prevention and/or treatment of diseases associated with EMT, including chronic cholestatic diseases, fibrosis and cholangiocarcinoma.
    Type: Application
    Filed: May 3, 2012
    Publication date: August 30, 2012
    Inventors: Matías Antonio Avila Zaragoza, Jesús Maria Bañales Asurmendi, Maria Carmen Berasain Lasarte, Fernando José Corrales Izquierdo, MarÍa del Carmen Gil Puig, María Ujue Latasa Sada, Jon Lecanda Cordero, Jesús Maria Prieto Valtueña, Carlos Manuel Rodríguez Ortigosa
  • Synergistic 5?-methylthioadenosine combinations
    Patent number: 8236778
    Abstract: The present invention relates to combinations of 5?-methylthioadenosine and glatiramer acetate, and to their use in the treatment of multiple sclerosis. In a particular embodiment, the present invention relates to a product comprising 5?-methylthioadenosine and glatiramer acetate as a combined preparation for the simultaneous, separate, or sequential use thereof for the prevention and/or treatment of multiple sclerosis.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: August 7, 2012
    Assignee: Proyecto de Biomedicina Cima, S.L.
    Inventors: Matías Antonio Ávila Zaragozá, Fernando José Corrales Izquierdo, Begoña Fernández Díez, Beatriz Moreno Bruna, Pablo Villoslada Díaz
  • SYNERGISTIC 5'-METHYLTHIOADENOSINE COMBINATIONS
    Publication number: 20110015132
    Abstract: The present invention relates to combinations of 5?-methylthioadenosine and glatiramer acetate, and to their use in the treatment of multiple sclerosis. In a particular embodiment, the present invention relates to a product comprising 5?-methylthioadenosine and glatiramer acetate as a combined preparation for the simultaneous, separate, or sequential use thereof for the prevention and/or treatment of multiple sclerosis.
    Type: Application
    Filed: March 18, 2009
    Publication date: January 20, 2011
    Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.
    Inventors: Matias Antonio Ávila Zaragozá, Fernando José Corrales Izquierdo, Begona Fernández Díez, Beatriz Moreno Bruna, Pablo Villoslada Díaz